Johnson & Johnson reported strong third-quarter results with all segments showing solid growth, particularly in Pharmaceuticals driven by key products like DARZALEX and IMBRUVICA. Management provided an optimistic outlook for 2018, raising both sales and EPS guidance, and emphasized strategic growth initiatives in emerging markets and medical devices. The positive performance and elevated guidance are likely to boost investor confidence in the short term.

[1]